This HTML5 document contains 47 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n18http://linked.opendata.cz/resource/drugbank/drug/DB00100/identifier/drugbank/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n10http://linked.opendata.cz/resource/mesh/concept/
n16http://linked.opendata.cz/resource/drugbank/company/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00100/identifier/national-drug-code-directory/
foafhttp://xmlns.com/foaf/0.1/
n23http://linked.opendata.cz/resource/drugbank/dosage/
n12http://bio2rdf.org/drugbank:
n21http://linked.opendata.cz/resource/drugbank/drug/DB00100/identifier/genbank/
admshttp://www.w3.org/ns/adms#
n14http://linked.opendata.cz/resource/drugbank/drug/DB00100/identifier/uniprotkb/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00100/identifier/wikipedia/
n26http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00100/identifier/pharmgkb/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n22http://linked.opendata.cz/resource/drugbank/medicinal-product/
n9http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n19http://linked.opendata.cz/resource/drugbank/drug/DB00100/identifier/kegg-compound/
n5http://linked.opendata.cz/ontology/drugbank/
n17http://www.drugs.com/cdi/
n8http://linked.opendata.cz/resource/drugbank/property/
n7http://www.rxlist.com/cgi/generic2/
xsdhhttp://www.w3.org/2001/XMLSchema#
n4http://linked.opendata.cz/resource/atc/
n3http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00100
rdf:type
n5:Drug
n5:description
Human Factor IX protein, produced by recombinant DNA technology for use in therapy of factor IX deficiency, known as hemophilia B or Christmas disease. Coagulation Factor IX (Recombinant) is a glycoprotein with an approximate molecular mass of 55,000 Da consisting of 415 amino acids in a single chain. It has a primary amino acid sequence that is identical to the Ala 148 allelic form of plasma-derived factor IX.
n5:dosage
n23:271B4532-363D-11E5-9242-09173F13E4C5 n23:271B4531-363D-11E5-9242-09173F13E4C5
n5:generalReferences
# BIGGS R, DOUGLAS AS, MACFARLANE RG, DACIE JV, PITNEY WR, MERSKEY: Christmas disease: a condition previously mistaken for haemophilia. Br Med J. 1952 Dec 27;2(4799):1378-82. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12997790 # Kurachi K, Davie EW: Isolation and characterization of a cDNA coding for human factor IX. Proc Natl Acad Sci U S A. 1982 Nov;79(21):6461-4. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/6959130
n5:group
approved
n5:halfLife
19.4 ± 5.4 hours (range from 11 to 36 hours)
n5:indication
For treatment of hemophilia (Christmas disease).
owl:sameAs
n12:DB00100 n26:DB00100
dcterms:title
Coagulation Factor IX
adms:identifier
n14:P00740 n18:DB00100 n19:C03101 n20:0053-7668-02 n21:K02402 n24:Factor_IX n25:PA164744952
n5:mechanismOfAction
Coagulation Factor IX is an important protein in the process of hemostasis and normal blood clotting. Factor IX is plays an important intermediate role in the blood coagulation cascade. It is located within the blood plasma as a zymogen, an antecedent to enzymatic function, in its inactivated state. Factor IX is dependent on the presence of Vitamin K, and is activated to a serine protease by the function of Coagulation Factor XIa. Factor XIa cleaves the peptide bond associated with protein activation in Factor IX, leaving Factor IX with two exposed chains, a light chain and a heavy chain. These two chains are held together by several disulfide bonds that reinforce the structure of Factor IX's activated form. After being activated, Factor IX forms a complex with calcium ions, membrane phospholipids and Coagulation Factor VIII to activate Coagulation Factor X. The activation of Factor X then performs a similarly integral step in the blood coagulation cascade. The ultimate result of phenotypically normal coagulation factors is the creation of platelets for normal blood clotting.
n5:packager
n16:271B4529-363D-11E5-9242-09173F13E4C5 n16:271B4527-363D-11E5-9242-09173F13E4C5 n16:271B4528-363D-11E5-9242-09173F13E4C5 n16:271B4526-363D-11E5-9242-09173F13E4C5
n5:synonym
Christmas factor Coagulation factor IX precursor Plasma thromboplastin component PTC
n5:synthesisReference
Volker Schellenberger, Joshua Silverman, Willem Stemmer, Chia-wei Wang, Benjamin Spink, Nathan Geething, Wayne To, "Coagulation factor IX compositions and methods of making and using same." U.S. Patent US20110046060, issued February 24, 2011.
n9:hasConcept
n10:M0008141
foaf:page
n7:factorix.htm n17:coagulation-factor-ix-injection-human.html
n5:Molecular-Formula
n8:271B4537-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n8:271B4536-363D-11E5-9242-09173F13E4C5
n3:hasATCCode
n4:B02BD04
n5:affectedOrganism
Humans and other mammals
n5:casRegistryNumber
9001-28-9
n5:category
n5:containedIn
n22:271B452A-363D-11E5-9242-09173F13E4C5 n22:271B452F-363D-11E5-9242-09173F13E4C5 n22:271B4530-363D-11E5-9242-09173F13E4C5 n22:271B452D-363D-11E5-9242-09173F13E4C5 n22:271B452E-363D-11E5-9242-09173F13E4C5 n22:271B452B-363D-11E5-9242-09173F13E4C5 n22:271B452C-363D-11E5-9242-09173F13E4C5
n5:Hydrophobicity
n8:271B4534-363D-11E5-9242-09173F13E4C5
n5:Isoelectric-Point
n8:271B4535-363D-11E5-9242-09173F13E4C5
n5:Melting-Point
n8:271B4533-363D-11E5-9242-09173F13E4C5